Japan's generics sales up 2.9%, but slowing

7 September 2008

Turnover of generic drugs in Japan for the 2007 fiscal year were worth 360.0 billion yen ($3.31 billion), a rise of 2.9% on the prior 12 months, but the advance was much lower than the 13% increase registered then, reports the Nikkei Weekly. Slower growth is forecast for this year.

The country's four leading copy drugmakers boosted their combined market share by 1.6 percentage points to 34.8%, achieving this by exploiting their brand name recognition through aggressive advertising campaigns, including on television, the newspaper noted.

Sector leader Sawai Pharmaceuticals lifted its generics market share 0.6 points to 10.4%, Towa Pharmaceuticals raised its percentage 0.3 points to 8.7%, third in line Taiyo Pharmaceutical Industry achieved an 8.0% share, up 0.2 points, and Nichi-Iko registered 7.7%, up 0.5 points.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight